Company intelligence / Profile preview

Biosyngen

Ownership: Private
Development stage: Phase 2

Overview

Leading pipeline product BRG01 is in pivotal Phase II clinical trials. BST02 and BRL03 are in Phase I trials with completion anticipated in 2025. BRG01 has received Orphan Drug Designation from the FDA.

Therapeutic areas: Oncology
Modalities: CAR-TTCR-TTILMulti-specific antibodiesCell Therapy
Industry: Biotech

Drug pipeline

15 assets

BSG-001

14 more assets in the full pipeline.

Request access →

Partnerships

Sun Yat-sen University Cancer CenterGuangzhou District Government

Beyond the preview

Go deeper on Biosyngen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biosyngen.

Explore the full profile